Clear leader
9 companies value 155 bn revenue 12 bn margin 24.8% free cash flow 3.0 bn avg. score 0.8
ISRG holds 98.6% of the group's value, 146.2x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ISRG | Intuitive Surgical United States · score 6.1 | 99% | 153 bn | 11 bn | 28.4% | 3.2 bn | 2.1% | — | da Vinci surgical robots and instruments · Practical monopoly in robotic surgery (da Vinci); recurring instrument revenue | |
| 2 | PRCT | PROCEPT BioRobotics United States · score 0.0 | 1% | 1.0 bn | 0.3 bn | -32.5% | -0.1 bn | -8.1% | — | Surgical robot for prostate treatment · Prostate surgery robot that is taking share from the traditional procedure | |
| 3 | SSII | SS Innovations International, Inc. India · score 0.1 | 0% | 0.5 bn | 0.1 bn | -25.7% | -0.0 bn | -3.7% | — | Broader-access surgical robots, from India · India — revenue of $48m | |
| 4 | CLPT | ClearPoint Neuro, Inc. United States · score 0.0 | 0% | 0.3 bn | 0.0 bn | -81.8% | -0.0 bn | -11.2% | — | Systems for minimally invasive neurosurgery · California — revenue of $42m | |
| 5 | PROF | Profound Medical Corp. Canada · score 0.0 | 0% | 0.2 bn | 0.0 bn | -171.6% | -0.0 bn | -16.9% | — | AI-powered, MRI-guided incision-free therapies · Canada — revenue of $19m | |
| 6 | STXS | Stereotaxis, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -74.2% | -0.0 bn | -15.3% | — | Robotic magnetic navigation for cardiac procedures · Missouri — revenue of $30m | |
| 7 | MBOT | Microbot Medical Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -28.1% | — | Robots for minimally invasive endoluminal surgery · Massachusetts | |
| 8 | FOCL | EDAP TMS SA France · score 0.6 | — | — | 0.1 bn | -49.1% | -0.0 bn | — | — | Ultrasound equipment for prostate cancer treatment, from France · France — revenue of $79m | |
| 9 | VTAK | Catheter Precision, Inc. United States · score 0.7 | — | — | 0.0 bn | -679.1% | -0.0 bn | — | — | Devices and robotics for cardiac procedures · South Carolina — revenue of $2m |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Clinical-stage pharmaceuticals 251 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
- Molecular testing and advanced diagnostics 42 companies
and 22 industries more
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.